We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The governors of four states yesterday petitioned the Food and Drug Administration in an attempt to force the agency to quickly clarify how generic versions of two drugs made from living organisms can be brought to market.
Pfizer Inc.'s newly appointed CEO Jeffrey B. Kindler will earn $1.35 million a year in base pay, a 42 percent raise over his salary as the company's general counsel, according to financial documents filed last week.
A California court has issued a $2.4 million judgment in a case brought by Caleel+Hayden against Valeant Pharmaceuticals International, Caleel+Hayden said.
The chief executive of pharmacy benefits manager Medco Health Solutions on Friday forecast that a generic form of Bristol-Myers Squibb Co.'s blockbuster anti-clotting drug Plavix would reach the U.S. market this year.
Amgen said that the appeals Court affirmed the District Court's decision that Transkaryotic Therapies Inc., or TKT, and Aventis Pharmaceuticals Inc. infringe Amgen's erythropoietin, or EPO, patent estate.
The FDA has sent the Oklahoma Blood Institute Institutional Review Board (IRB) a warning letter over its failure to follow meeting and documentation procedures.
The House passed a sweeping health information technology (HIT) bill that includes a provision designed to boost the use of electronic clinical trial data, but the measure came under swift attack by Democrats who charged that it would not improve technology adoption but would endanger the privacy of patient medical records.
Patent litigation will recommence between sanofi-aventis, Bristol-Myers Squibb (BMS) and Apotex after state officials rejected a proposed patent settlement where Apotex would be paid to defer launching a generic version of the blockbuster blood thinner Plavix, sanofi-aventis said Aug. 2.